{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"ARIAN","nct_id":"NCT06431633","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=arian-nct06431633. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ARIAN","arms":[{"description":"Patients randomized in this arm will be in observation for 10 months. It is allowed to administer adjuvant treatment according to investigator criteria. Immunotherapy is not allowed in this arm, only chemotherapy treatment is allowed.","label":"ARM 1: Observation-investigator decision","type":"ACTIVE_COMPARATOR"},{"description":"Adjuvant treatment with Zimberelimab will start between the 3rd to the 10th week from surgery. 13 cycles will be administered in total. Cycles will be administered in 21-day intervals (Q3W).\n\nZimberelimab: day 1 360 mg IV Q3W (13 cycles)","label":"ARM 2: Immunotherapy. Zimberelimab treatment for 13 cycles","type":"EXPERIMENTAL"},{"description":"Sacituzumab Govitecan: day 1 and 8; 10mg/Kg IV Q3W Zimberelimab: day 1 360 mg IV Q3W\n\nTreatment sequence:\n\nAdjuvant treatment will start between the 3rd to the 10th week from surgery. 13 cycles will be administered in total. Cycles will be administered in 21-day intervals (Q3W).\n\nPatients will receive 8 cycles of Sacituzumab Govitecan + Zimberelimab and 5 cycles of Zimberelimab monotherapy.","label":"ARM 3: Sacituzumab Govitecan + Zimberelimab for 8 cycles + Zimberelimab for 5 cycles","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2031-11-30","type":"ESTIMATED"},"conditions":["Lung Diseases","Carcinoma, Non-Small-Cell Lung","Resectable Lung Non-Small Cell Carcinoma"],"enrollment":{"count":129,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Zimberelimab","otherNames":["anti-PD-1 monoclonal antibody AB122"],"type":"DRUG"},{"name":"Sacituzumab govitecan","otherNames":["Trodelvy"],"type":"DRUG"},{"name":"Cisplatin","otherNames":["Platinol"],"type":"DRUG"},{"name":"Carboplatin","otherNames":["Paraplatin"],"type":"DRUG"}],"last_update":"2026-05-18","lead_sponsor":"Fundación GECP","official_title":"A Phase III Clinical Trial of Adjuvant Treatment With Sacituzumab and Zimberelimab for Stage IB-IIIA-IIIB(N2) Previously Resected (R0) Non-small Cell Lung Cancer Patients That Did Not Achieve Pathological Complete Response After Neoadjuvant treatment_ARIAN","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2031-11-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease free survival","timeFrame":"The time from random assignment to cancer recurrence or death from any cause, assessed up to 36 months"}],"references":[],"start_date":{"date":"2025-02-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.","url":"https://clinicaltrials.gov/study/NCT06431633"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/arian-nct06431633"}